Dávid Papp

Mr. Dávid Papp

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DPDomonkos Pál
Domonkos Pál
GTGabor Toth
Gabor Toth
Simon SugárSimon Sugár
Simon Sugár
KFKata Dorina Fügedi
Kata Dorina Fügedi
DSDániel Szabó
Dániel Szabó
LTLilla Turiák
Lilla Turiák
Lung cancer is one of the most commonly diagnosed cancer types. Studying the molecular changes that occur in lung cancer is important to understand tumor formation and identify new therapeutic targets and early markers of the disease to decrease mortality. Glycosaminoglycan chains play important roles in various signaling events in the tumor microenvironment. Therefore, we have determined the quantity and sulfation characteristics of chondroitin sulfate and heparan sulfate in formalin-fixed paraffin-embedded human lung tissue samples belonging to different lung cancer types as well as tumor adjacent normal areas. Glycosaminoglycan disaccharide analysis was performed using HPLC-MS following on-surface lyase digestion. Significant changes were identified predominantly in the case of chondroitin sulfate; for example, the total amount was higher in tumor tissue compared to the adjacent normal tissue. We also observed differences in the degree of sulfation and relative proportions of individual chondroitin sulfate disaccharides between lung cancer types and adjacent normal tissue. Furthermore, the differences in the 6-O-/4-O-sulfation ratio of chondroitin sulfate were different between the lung cancer types. Our pilot study revealed that further investigation of the role of chondroitin sulfate chains and enzymes involved in their biosynthesis is an important aspect of lung cancer research.

Verified
Journal Article
Open access
PDF file
DVDávid Virág
Dávid Virág
GSGitta Schlosser
Gitta Schlosser
ABAdina Borbely
Adina Borbely
GGGabriella Gellen
Gabriella Gellen
DPDávid Papp
Dávid Papp
KLKrisztina Ludányi
Krisztina Ludányi
Mass spectrometry has become the most prominent yet evolving technology in quantitative proteomics. Today, a number of label-free and label-based approaches are available for the relative and absolute quantification of proteins and peptides. However, the label-based methods rely solely on the employment of stable isotopes, which are expensive and often limited in availability. Here we propose a label-based quantification strategy, where the mass difference is identified by the differential alkylation of cysteines using iodoacetamide and acrylamide. The alkylation reactions were performed under identical experimental conditions; therefore, the method can be easily integrated into standard proteomic workflows. Using high-resolution mass spectrometry, the feasibility of this approach was assessed with a set of tryptic peptides of human serum albumin. Several critical questions, such as the efficiency of labeling and the effect of the differential alkylation on the peptide retention and fragmentation, were addressed. The concentration of the quality control samples calculated against the calibration curves were within the ±20% acceptance range. It was also demonstrated that heavy labeled peptides exhibit a similar extraction recovery and matrix effect to light ones. Consequently, the approach presented here may be a viable and cost-effective alternative of stable isotope labeling strategies for the quantification of cysteine-containing proteins.

Verified
Journal Article
Open access
PDF file
EFEtelka Ferenczi
Etelka Ferenczi
PKPéter Keglevich
Péter Keglevich
Bizhar Ahmed TayebBizhar Ahmed Tayeb
Bizhar Ahmed Tayeb
RMRenáta Minorics
Renáta Minorics
DPDávid Papp
Dávid Papp
Antal CsampaiAntal Csampai
Antal Csampai
In the frame of our diversity-oriented research on multitarget small molecule anticancer agents, utilizing convergent synthetic sequences terminated by Sonogashira coupling reactions, a preliminary selection of representative alkyne-tethered vindoline hybrids was synthesized. The novel hybrids with additional pharmacophoric fragments of well-documented anticancer agents, including FDA-approved tyrosine-kinase inhibitors (imatinib and erlotinib) or ferrocene or chalcone units, were evaluated for their antiproliferative activity on malignant cell lines MDA-MB-231 (triple negative breast cancer), A2780 (ovarian cancer), HeLa (human cervical cancer), and SH-SY5Y (neuroblastoma) as well as on human embryonal lung fibroblast cell line MRC-5, which served as a reference non-malignant cell line for the assessment of the therapeutic window of the tested hybrids. The biological assays identified a trimethoxyphenyl-containing chalcone-vindoline hybrid (36) as a promising lead compound exhibiting submicromolar activity on A2780 cells with a marked therapeutic window.

Verified
Journal Article
Open access
PDF file
TCTamás Czuczi
Tamás Czuczi
JMJózsef Murányi
József Murányi
IMIstván András Móra
István András Móra
Bianka GurbiBianka Gurbi
Bianka Gurbi
AVAttila Varga
Attila Varga
Antal CsampaiAntal Csampai
Antal Csampai
Our ongoing research focuses on the development of new imipridone derivatives. We aim to design compounds that can completely and selectively eradicate cancer cells after relatively short treatment. We have synthetized systematically designed novel hybrids and evaluated their antiproliferative activity against PANC-1 and Fadu cell lines. We have also conducted preliminary studies on the mechanism, including colony formation as well as dose–response tests in HEK293T wild-type (WT) and HEK293T CLPP−/− cells. Following gradual structural fine-tuning based on high throughput screening, we identified two imipridone hybrids as the most potent derivatives. Their unique substitution pattern includes N-methylated propargylamine and ferrocenyl/phenyltriazole moieties on the benzyl groups attached to opposite sides of the imipridone core. We found that the compounds with IC50 values similar to those of ONC201 completely eradicated cancer cells at about 4 μM, while ONC201 treatment at even higher concentrations left 30–50% of viable cells behind. Both compounds exerted equal activity in WT and CLPP−/− HEK293T cells, indicating a ClpP-independent mechanism. Further development is needed to improve the tumor selectivity of the two potent imipridone derivatives. By preserving tumor cytotoxicity, we aim to generate new drug candidates that evade resistance and can be applied in a sufficiently broad therapeutic window.

24 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TCTamás Czuczi
Tamás Czuczi
JMJózsef Murányi
József Murányi
IMIstván András Móra
István András Móra
Bianka GurbiBianka Gurbi
Bianka Gurbi
AVAttila Varga
Attila Varga
Antal CsampaiAntal Csampai
Antal Csampai
Our ongoing research focuses on developing imipridone derivatives capable of complete and selective eradication of cancer cells after relatively short treatment. We have synthetized systematically designed novel hybrids and evaluated their antiproliferative activity on PANC-1 and Fadu cell lines. We have also conducted preliminary studies on the mechanism including colony formation as well as dose-response tests in HEK293T wild-type (WT) and HEK293T CLPP-/- cells. Following gradual structural fine-tuning based on high throughput screening we identified two imipridone hybrids as the most potent derivatives. Their unique substitution pattern includes N-methylated propargylamine and ferrocenyl/phenyltriazole moieties on the benzyl groups attached to opposite sides of the imipridone core. The compounds with IC50 values similar to those of ONC201 were found capable of complete eradication of cancer cells at ca. 4 M, while ONC201 treatment at even higher concentrations left 30-50% of viable cells behind. Both compounds were found to exert equal activity in WT and CLPP-/- HEK293T cells, indicating a ClpP-independent mechanism. Further development is needed to improve the tumor selectivity of the two potent imipridone derivatives in order to develop novel drug candidates that evade resistance and can be applied in a sufficiently broad therapeutic window.

29 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRamila Mammadova
Ramila Mammadova
FPFeby Pratiwi
Feby Pratiwi
CLCarmen Laezza
Carmen Laezza
KSKeerthanaa Balasubramanian Shanthi
Keerthanaa Balasubramanian Shanthi
DPDávid Papp
Dávid Papp
Seppo VainioSeppo Vainio
Seppo Vainio
Cloudberry ( Rubus chamaemorus L.)-derived nanovesicles (NVs) represent a promising but still poorly characterized class of plant-derived vesicles with potential relevance for skin-related applications. Here, we isolated cloudberry fruit-derived NVs and investigated their physicochemical and molecular properties, cellular uptake, cytocompatibility, and functional effects in human dermal fibroblasts (HDF) and HaCaT keratinocytes. Nanoparticle tracking analysis and transmission electron microscopy confirmed a nanosized vesicle preparation with characteristic round morphology, while protein quantification supported reproducible isolation of NV-associated material. In vitro, cloudberry NVs showed concentration-dependent effects on cell viability and proliferation, with lower doses being better tolerated. Labelled NVs were internalized by both HDF and HaCaT cells in a time-dependent manner. Under oxidative stress conditions, cloudberry NVs reduced H 2 O 2 -induced senescence-associated β-galactosidase staining in HDFs and exerted cytoprotective effects in both cell lines, alongside measurable cell-free antioxidant activity in the DPPH assay. In scratch wound-healing assays, cloudberry NVs modulated wound closure in a dose-dependent manner, with the lowest tested concentration showing the most favorable response. UHPLC-MS/MS-based proteomics and metabolomics further indicated the presence of diverse secondary metabolites and stress-related protein cargo. Together, these results support the view that cloudberry-derived NVs are biologically active plant nanovesicles with potential utility in skin-related regenerative applications. Graphical